Alamar Biosciences, Alzheimer's Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer's Disease.
Multi-center project will profile over 40,000 samples using ultra-sensitive NULISA™ technology.
FREMONT, Calif., June 10, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, the Alzheimer's Disease Data Initiative and Gates Ventures today announced a strategic partnership with the goal to generate one of the largest proteomic datasets linked to clinical outcomes in Alzheimer's Disease (AD). This international project will profile over 40,000 plasma samples representing AD and related dementias using Alamar's ultra-sensitive NULISA™ technology, with the goal of accelerating biomarker discovery and driving new insights into the progression and treatment of AD.
"This collaboration reflects our shared commitment to transform the landscape of Alzheimer's research through data, technology, and global partnerships," said Yuling Luo, PhD, Founder, Chairman and CEO of Alamar Biosciences. "By combining our NULISA platform with Alzheimer's Disease Data Initiative's infrastructure and Gates Venture's mission-driven investment, we aim to catalyze a new era of biomarker-driven discovery and therapeutic development."
As part of the initiative, Alamar's NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 will be implemented at research centers in the United States, Sweden, United Kingdom, and India. These panels deliver unparalleled sensitivity and specificity, enabling the accurate measurement of hundreds of brain- and immune-related proteins from just a small volume of blood or cerebrospinal fluid. A key feature of the CNS panel is its unique ability to distinguish brain-derived phosphorylated tau from total phosphorylated tau in blood—a critical advancement for the development of community-based screening programs. The resulting proteomic data will be integrated with clinical and longitudinal outcome measures and shared with the global research community by leveraging the Global Neurodegeneration Proteomics Consortium 's (GNPC) secure data-sharing processes.
"Understanding the biological underpinnings of Alzheimer's Disease is essential for developing effective treatments," said Niranjan Bose, Managing Director of Health & Life Sciences at Gates Ventures and interim Executive Director of the Alzheimer's Disease Data Initiative. "This initiative will provide a rich resource to researchers worldwide and help overcome long-standing barriers in early detection and stratified interventions."
This initiative represents a major step forward in building a comprehensive, clinically annotated Alzheimer's plasma proteome atlas, with the potential to unlock new biomarkers for diagnosis, prognosis, and therapeutic response. This strategic collaboration complements the efforts of the GNPC, which has brought together top dementia researchers and datasets to collaborate and create one of the largest disease-specific proteomics datasets ever assembled. The project also emphasizes inclusivity by incorporating diverse cohorts from multiple geographic and ethnic populations.
About the Alzheimer's Disease Data Initiative
The Alzheimer's Disease Data Initiative is a coalition of leading academic, advocacy, government, industry, and philanthropy organizations that recognizes the need for dementia researchers to find easier ways to share data, analytical tools, and scientific findings. These partners are working together to accelerate progress towards new diagnostics, treatments, and cures for Alzheimer's disease and related dementias. Learn more about the Alzheimer's Disease Data Initiative at www.alzheimersdata.org.
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
4 days ago
- Korea Herald
Alamar Biosciences, Alzheimer's Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer's Disease.
Multi-center project will profile over 40,000 samples using ultra-sensitive NULISA™ technology. FREMONT, Calif., June 10, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, the Alzheimer's Disease Data Initiative and Gates Ventures today announced a strategic partnership with the goal to generate one of the largest proteomic datasets linked to clinical outcomes in Alzheimer's Disease (AD). This international project will profile over 40,000 plasma samples representing AD and related dementias using Alamar's ultra-sensitive NULISA™ technology, with the goal of accelerating biomarker discovery and driving new insights into the progression and treatment of AD. "This collaboration reflects our shared commitment to transform the landscape of Alzheimer's research through data, technology, and global partnerships," said Yuling Luo, PhD, Founder, Chairman and CEO of Alamar Biosciences. "By combining our NULISA platform with Alzheimer's Disease Data Initiative's infrastructure and Gates Venture's mission-driven investment, we aim to catalyze a new era of biomarker-driven discovery and therapeutic development." As part of the initiative, Alamar's NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 will be implemented at research centers in the United States, Sweden, United Kingdom, and India. These panels deliver unparalleled sensitivity and specificity, enabling the accurate measurement of hundreds of brain- and immune-related proteins from just a small volume of blood or cerebrospinal fluid. A key feature of the CNS panel is its unique ability to distinguish brain-derived phosphorylated tau from total phosphorylated tau in blood—a critical advancement for the development of community-based screening programs. The resulting proteomic data will be integrated with clinical and longitudinal outcome measures and shared with the global research community by leveraging the Global Neurodegeneration Proteomics Consortium 's (GNPC) secure data-sharing processes. "Understanding the biological underpinnings of Alzheimer's Disease is essential for developing effective treatments," said Niranjan Bose, Managing Director of Health & Life Sciences at Gates Ventures and interim Executive Director of the Alzheimer's Disease Data Initiative. "This initiative will provide a rich resource to researchers worldwide and help overcome long-standing barriers in early detection and stratified interventions." This initiative represents a major step forward in building a comprehensive, clinically annotated Alzheimer's plasma proteome atlas, with the potential to unlock new biomarkers for diagnosis, prognosis, and therapeutic response. This strategic collaboration complements the efforts of the GNPC, which has brought together top dementia researchers and datasets to collaborate and create one of the largest disease-specific proteomics datasets ever assembled. The project also emphasizes inclusivity by incorporating diverse cohorts from multiple geographic and ethnic populations. About the Alzheimer's Disease Data Initiative The Alzheimer's Disease Data Initiative is a coalition of leading academic, advocacy, government, industry, and philanthropy organizations that recognizes the need for dementia researchers to find easier ways to share data, analytical tools, and scientific findings. These partners are working together to accelerate progress towards new diagnostics, treatments, and cures for Alzheimer's disease and related dementias. Learn more about the Alzheimer's Disease Data Initiative at About Alamar Biosciences, Inc. Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit
Korea Herald
07-06-2025
- Korea Herald
HIRONIC Successfully Hosts First Asia Innovation Summit 2025
SEOUL, South Korea, June 7, 2025 /PRNewswire/ -- HIRONIC, a global leader in non-invasive medical aesthetic technology, has successfully hosted its inaugural 'HIRONIC Innovation Summit 2025. Asia Edition' in Bangkok, Thailand on June 5th. The event brought together approximately 100 medical professionals and medical distribution industry representatives from South Korea, Thailand, Vietnam, Malaysia, Indonesia, Myanmar, and other countries. Across four in-depth clinical sessions, speakers presented the latest approaches to skin rejuvenation, covering multi-layered face and body lifting, advanced scar treatment, and next-generation needle-free drug delivery technologies. One of the keynote lectures was delivered by Dr. Wonkyu Hong, Director and dermatologist at Human Dermatology Clinic and Executive Director of the Human Clinical Trial Center in South Korea. Dr. Hong explored the rapidly evolving role of needle-free technology in aesthetic medicine, sharing his clinical experience while emphasizing both its therapeutic advantages and its significant market growth potential driven by increasing patient demand for non-invasive rejuvenation solutions. Dr. Thitikom Limrattanamekha, founder and CEO of Optima Aesthetics in Thailand and an experienced laser specialist in scar treatment, skin quality improvement, and pigmentation management, shared his expertise on combining pico laser and RF microneedling to achieve highly effective outcomes in complex scarring cases. His presentation highlighted how advanced combination protocols are reshaping non-surgical treatment approaches and expanding therapeutic options for physicians worldwide. The symposium also provided a platform to showcase the clinical advancements and growing market relevance of HIRONIC's flagship export technologies, including New Doublo™, PICOHI™, and the latest needle-free delivery system Synerjet PRO™. Sasha Borovtsova, Head of Global Marketing Office at HIRONIC, stated, "This summit not only showcased the real-world clinical applications of our technologies but also underscored the accelerating global demand for safer, more versatile, and highly effective aesthetic solutions. As innovation continues to drive market growth, HIRONIC remains committed to advancing technology and strengthening global expertise and partnerships through events like the HIRONIC Innovation Summit." Headquartered in South Korea, HIRONIC is a leading global manufacturer of medical aesthetic devices, specializing in HIFU, RF, laser, and needle-free technologies. With a presence in over 80 countries, HIRONIC has introduced iconic devices such as Doublo™, Doublo Gold™, and New Doublo 2.0™ to the international market.
Korea Herald
04-06-2025
- Korea Herald
Kontron Launches Brand-new 2.5"-SBC-AML/ADN Single Board Computer To Help Developers Realize Ultra-compact Or Portable AI-native Systems
TAIPEI, June 4, 2025 /PRNewswire/ -- Kontron, a global leader in smart IoT solutions, launches a brand-new Pico-ITX single board computer, 2.5"-SBC-AML/ADN, providing developers a low-power, real-time and AI-native computing platform to realize ultra-compact or even portable computing systems and appliances for diverse edge applications, including industrial automation, healthcare, smart city, smart retail, office automation, safety and security. Commercial & Industrial Variants Available 2.5"-SBC-AML/ADN is driven by commercial-grade Intel® Atom® x7000E Series, Intel® Core™ i3 N-Series, Intel® N-Series processors and industrial-grade Intel® Atom® x7000RE Series processors. To better unleash the processor's features, it is offered with commercial-grade operating temperature range of 0°C ~ 60°C and industrial-grade range of -40°C ~ 85°C to address more applications. More Power in Small Footprint In contrast to its footprint of around a credit card, 2.5"-SBC-AML/ADN unleashes incredible graphics performance. Three 4K@60fps displays can be driven via eDP, DisplayPort and DisplayPort over USB-C interfaces. Up to 32 execution units in iGPU and Intel® Deep Learning Boost AI acceleration capabilities deliver faster AI inference performance. What's more, all are enabled at a low TDP of 6W ~ 15W. Low Latency & Real-time 2.5"-SBC-AML/ADN is outfitted with high-speed soldered LPDDR5 4800MHz SDRAM, two higher-bandwidth 2.5GbE LAN ports, and three 10Gbps USB 3.2 Gen 2 Type A & C connectors, achieving ultra-low latency within and between the system and peripherals. Partial variants support Time-Sensitive Networking, ensuring real-time network responsiveness. More Rugged & Securer Besides soldered memory, 2.5"-SBC-AML/ADN comes with soldered eMMC storage and has intrinsic resistance to shock and vibration. It operates over a wide input range from DC 9V to 20V to accommodate to unstable power supply, surge or various voltage requirements in different applications. A discrete TPM 2.0 chip is integrated, providing securer hardware-based encryption. Uncompromising Connectivity & Expandability Despite its small footprint, 2.5"-SBC-AML/ADN doesn't skimp on connectivity and expandability. It reserves wiring interface options, including two COM ports and eight digital I/O channels, for industrial sensing and controlling, and two M.2 slots for Wi-Fi, 4G/5G, SSD or other possible expansions.
